Antithrombotic Drugs Market by Route of Administration, Distribution Channel, and Geography - Forecast and Analysis 2023-2027

Antithrombotic Drugs Market Forecast 2023-2027

The antithrombotic drugs market is estimated to increase by USD 23.20 billion and grow at a CAGR of 8.42% between 2022 and 2027. Market growth hinges on various factors, such as the increasing incidence of coagulation disorders, the emergence of novel oral anticoagulants, and robust research and development activities. However, challenges persist, including the significant side effects associated with anticoagulant drugs, the widespread availability of generic alternatives, and a prevailing preference for blood clot surgeries over antithrombotic medications.

What will be the Size of the Antithrombotic Drugs Market During the Forecast Period?

To learn more about this report, View Report Sample

Segmentation

This market report extensively covers market segmentation by route of administration (oral and injectable), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

By Route of Administration

The market share growth by the oral segment will be significant during the forecast period. The growing popularity of prescription-based drugs, such as oral capsules, is driving the growth of the segment.

Get a glance at the market contribution of various segments View the PDF Sample

The oral segment was valued at USD 19.87 billion in 2017 and continued to grow until 2021. The growing number of clinical trials and collaborations are further fueling the segment's growth. For instance, in March 2023, Bristol Myers Squibb collaborated with Janssen Pharmaceuticals and announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor FXIa inhibitor for the antithrombotic drug. The drug can treat conditions associated with a thrombotic event and patient bleeding. Anticoagulants, warfarin, clopidogrel, and aspirin are other oral drugs used to treat thrombosis. These factors will drive the growth of the segment during the forecast period. 

By Regions

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The US and Canada are the leading revenue-generating countries in North America due to the increasing prevalence of deep vein thrombosis and pulmonary embolism.  Factors such as the increasing awareness of the severity of diseases such as DVT and pulmonary embolism and the advanced healthcare system in the US play a key role in driving the growth of the regional market's growth. This is increasing the growth prospects for the market in the region. The market in North America has many approved therapies, such as warfarin therapy and antiplatelet therapy. Some of these pipeline molecules are expected to be launched during the forecast period. Thus, the market in North America is expected to grow at a significant rate during the forecast period.

Market Dynamics and Customer Landscape

The market is experiencing significant growth driven by factors such as the increasing prevalence of hypertension and cardiovascular emergencies. With strict lockdown procedures in place, the demand for novel oral anticoagulants is on the rise, especially among the aging population. Conditions like coronary heart disease and atrial fibrillation contribute to the growing need for antithrombotic drugs. Despite regulatory policies, concerns about side effects persist. These drugs play a crucial role in preventing the formation of blood clots, particularly in patients with chronic diseases like diabetes mellitus and cancer. The market's trajectory is also influenced by the efficacy of antiplatelet drugs and thrombolytic medications, emphasizing the importance of oral administration routes and the body's clotting mechanisms. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The market growth is significantly driven by the increasing prevalence of coagulation disorders. With cardiovascular emergencies and strict lockdown procedures affecting lifestyles, the incidence of conditions like deep vein thrombosis and pulmonary embolism is on the rise. This surge in health issues, particularly among the aging population, underscores the need for antithrombotic drugs to manage thromboembolic and hemorrhagic complications. As cardiovascular diseases and chronic conditions become more prevalent, the demand for antithrombotic medications, such as novel oral anticoagulants and antiplatelet drugs, is expected to escalate. This trend highlights a promising outlook for the market in the forecast period.

Significant Market Trends

The advent of anticoagulant antidotes is a key trend in the market. The preference for oral anticoagulants was low despite the high efficacy of oral anticoagulants in the treatment of thrombosis. This is primarily due to numerous adverse side effects, such as bruising, prolonged nosebleeds, and vomiting blood. The market did not have any antidotes for novel oral anticoagulants, which posed a challenge to the growth of the market. 

Antidotes reverse the side effects caused by anticoagulants and help the body regain its ability to clot blood. Pharmaceutical players are researching antidotes for the treatment of thrombosis. The positive results of these antidotes in clinical trials have increased their chances of approval. The pipeline has a few antidotes that are expected to gain approval during the forecast period. Key vendors are expected to launch antidotes, which, in turn, will support market growth during the forecast period.

Major Market Challenge

Strong side effects of anticoagulant drugs will challenge market growth. Anticoagulants or blood thinners are medications developed to dissolve blood clots. However, they have various side effects. They decrease the ability of blood to clot, thereby slowing down the blood clotting process. As a result, the flow of blood becomes uncontrollable.

The long-term use of anticoagulants is associated with cardiovascular risks, such as strokes and heart attacks. Some other side effects associated with using anticoagulants are severe bruising, prolonged nosebleeds, and vomiting blood. The use of anticoagulants is also associated with severe back pain, chest pain, dizziness, headaches, and jaundice. As a result, the use of these drugs is increasing. Therefore, the rising awareness about the side effects of anticoagulants is expected to hinder the growth of the global market during the forecast period.

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Antithrombotic Drugs Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Aspen Pharmacare Holdings Ltd - The company offers anti-thrombotic drugs such as Fraxiparine.

The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

• AbbVie Inc.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Co.
• Daiichi Sankyo Co. Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals Plc
• Johnson and Johnson Services Inc.
• Merck and Co. Inc.
• Novartis AG
• Otsuka Pharmaceutical Co. Ltd.
• Pfizer Inc.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Segment Overview

The market report forecasts market growth by revenue at global, regional, & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Route of Administration Outlook 
  • Oral
  • Injectable

• Distribution Channel Outlook
  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Australia
    • Argentina
    • Rest of the world

Market Analyst Overivew

The market is propelled by various factors, including the increasing prevalence of cardiovascular emergencies like coronary heart disease and peripheral arterial disease, alongside the rising incidence of atrial fibrillation among the ageing population. Amid strict lockdown procedures, the demand for antithrombotic medications for hypertension and diabetes management has surged. Regulatory policies from institutions like the Centers for Disease Control and Prevention (CDC) guide the market landscape. Notable medications such as dabigatran etexilate play a crucial role in treating conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE). This market addresses a wide array of chronic diseases, including cancer, by offering effective treatments through oral routes and thrombolytic drugs, ensuring improved arterial and venous circulation.

Moreover, the market is experiencing significant growth, driven by various factors such as the prevalence of hypertension, heart conditions, and coronary (ischemic) heart disease. These medications play a crucial role in managing cardiovascular diseases, including peripheral arterial (vascular) disease, and reducing the risk of thrombotic events. Antithrombotic drugs, including antiplatelet drugs and thrombolytic medications, are administered orally to inhibit the formation of blood clots. They target different aspects of the body's ability to form blood clots, such as interfering with the production of vitamin K in the liver. This market addresses a wide range of thrombotic conditions, including arterial thrombosis and venous thrombosis, offering various types of antithrombotic agents like Vitamin K Antagonists, Glycoproteins, and Direct Thrombin Inhibitors. Despite challenges like the side effects of anticoagulant drugs and the preference for blood clot surgeries, the effectiveness and advantages of antithrombotic drugs continue to drive their adoption, particularly in managing cardiovascular diseases and thrombotic events.

In the realm of modern healthcare, addressing a spectrum of health concerns ranging from hypertension treatment to joint replacement surgery has become paramount. This article delves into key aspects of various medical conditions and treatment modalities, all aimed at enhancing patient well-being and quality of life. Hypertension, commonly known as high blood pressure, stands as a pervasive health issue worldwide. Effective hypertension treatment strategies play a pivotal role in mitigating associated risks such as heart and circulatory diseases. Individuals afflicted with hypertension must adhere to prescribed medications and lifestyle modifications to manage their condition and prevent complications.

Furthermore, venous thromboembolism, a potentially life-threatening condition characterized by blood clots in the veins, requires prompt intervention. Antithrombotic and anticoagulant medications serve as frontline treatments to prevent clot formation and minimize the risk of complications such as pulmonary embolism. Obesity, a burgeoning global epidemic, poses multifaceted challenges to public health. Alongside dietary modifications and exercise regimens, addressing obesity often necessitates comprehensive weight management strategies tailored to individual needs. 

In the realm of cardiovascular health, antithrombotic and anticoagulant medications play a pivotal role in preventing thrombus formation and reducing the risk of adverse cardiovascular events. These medications, administered via the oral route, offer convenience and efficacy in managing heart-related ailments, including atrial fibrillation and thromboembolic disorders. In conclusion, advancements in medical science have revolutionized the management of diverse health concerns, from hypertension treatment to joint replacement surgery. By leveraging innovative treatment modalities and adopting a holistic approach to patient care, healthcare providers strive to improve patient outcomes and enhance overall quality of life. However, it remains imperative for individuals to prioritize preventive measures and adhere to prescribed treatment regimens to safeguard their health and well-being.

Antithrombotic Drugs Market Scope
Report Coverage	Details
Page number	156
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 8.42%
Market growth 2023-2027	USD 23.20 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	7.44
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 41%
Key countries	US, Canada, Japan, Germany, and UK
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Aspen Pharmacare Holdings Ltd, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Fresenius Kabi AG
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View PDF Sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. 

Get in touch